STOCK TITAN

Collegium Pharmaceutical, Inc. - $COLL STOCK NEWS

Welcome to our dedicated page for Collegium Pharmaceutical news (Ticker: $COLL), a resource for investors and traders seeking the latest updates and insights on Collegium Pharmaceutical stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Collegium Pharmaceutical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Collegium Pharmaceutical's position in the market.

Rhea-AI Summary
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced that the U.S. Court of Appeals for the Federal Circuit upheld the judgment of the Patent Trial and Appeal Board (PTAB) in its final decision that Purdue’s ‘961 patent, which Purdue has claimed is infringed by Xtampza® ER, is invalid. The Federal Circuit’s decision confirms both that the PTAB had statutory authority to issue its final decision, and that the PTAB did correctly conclude that the ʼ961 patent was invalid.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
none
-
Rhea-AI Summary
COLL: Collegium Pharmaceutical Announces $25 Million Accelerated Share Repurchase Agreement with Jefferies LLC, part of $100 million share repurchase program. President and CEO Joe Ciaffoni highlights record financial performance and commitment to returning value to shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.58%
Tags
buyback
-
Rhea-AI Summary
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) to participate in investor conferences. Fireside chats at Jefferies 14th Annual Global Healthcare Conference on Nov 14 and Piper Sandler 35th Annual Healthcare Conference on Nov 28. Webcast available on company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.6%
Tags
conferences
Rhea-AI Summary
COLL: Collegium Pharmaceutical Reports Q3'23 Net Revenue of $136.7 Million, Up 8% YoY, Records Adjusted EBITDA of $89.4 Million, and Extends Nucynta Regulatory Exclusivity through July 2026
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.6%
Tags
-
Rhea-AI Summary
Collegium Pharmaceutical will report its Q3 2023 financial results on November 7, 2023, followed by a conference call and webcast. Access details provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.3%
Tags
conferences earnings
-
Rhea-AI Summary
Collegium Pharmaceutical will present 10 posters at PAINWeek Conference 2023, highlighting data on their pain portfolio. The presentations will provide insights for healthcare decision makers. No concrete business takes affecting stock price.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.59%
Tags
none
Rhea-AI Summary
Collegium Pharmaceutical receives New Patient Population exclusivity for Nucynta, extending U.S. exclusivity period from June 2025 to July 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.04%
Tags
none
-
Rhea-AI Summary
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announces an Accelerated Share Repurchase agreement with Jefferies LLC to repurchase $50 million of the Company’s common stock, reinforcing confidence in Collegium's core business and financial strength. The ASR is part of a $100 million share repurchase program authorized by its Board of Directors in January 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.38%
Tags
buyback
-
Rhea-AI Summary
Collegium Pharmaceutical reports Q2'23 net revenue of $135.5M, up 10% YoY. Q2'23 GAAP net income of $13.0M. Q2'23 adjusted EBITDA of $85.8M, up 21% YoY. Board authorizes $50M share repurchase program. Reaffirms full-year 2023 guidance. Conference call scheduled for today at 4:30 p.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.68%
Tags
none
Rhea-AI Summary
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) to Report Q2 2023 Financial Results on August 3, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
conferences earnings
Collegium Pharmaceutical, Inc.

Nasdaq:COLL

COLL Rankings

COLL Stock Data

1.11B
28.80M
1.41%
122.63%
21.76%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
STOUGHTON

About COLL

collegium pharmaceutical, inc. is a specialty pharmaceutical company developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. with a substantial number of patients suffering from chronic pain, collegium is committed to developing and commercializing a portfolio of products that address the growing problems associated with non-medical use, abuse and misuse of prescription products by leveraging the company’s proprietary deterx® technology platform. deterx technology can be used with drugs that are commonly abused such as opioids and amphetamines, as well as drugs that have a narrow therapeutic index that would benefit from protection against misuse such as breaking, crushing, grinding, or dissolving the product. the deterx technology platform is covered by u.s. and international patents and patent applications. collegium’s lead product candidate, xtampza er™, is an abuse-deterrent, ex